The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease
- PMID: 19042160
- DOI: 10.1016/S1474-4422(08)70262-X
The SERAD study of the safety and efficacy of galantamine in severe Alzheimer's disease
Comment on
-
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.Lancet Neurol. 2009 Jan;8(1):39-47. doi: 10.1016/S1474-4422(08)70261-8. Epub 2008 Nov 29. Lancet Neurol. 2009. PMID: 19042161 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
